Performance of an Industry Player Apellis Pharmaceuticals, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Biohaven Pharmaceutical Holding Company Ltd. (BHVN), has gained 1.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2022. Biohaven Pharmaceutical Holding Company Ltd. reported revenues of $215.08 million in the last reported quarter, representing a year-over-year change of +131.4%. EPS of -$6.21 for the same period compares with -$3.23 a year ago. Biohaven Pharmaceutical Holding Company Ltd. is expected to post a loss of $2.35 per share for the current quarter, representing a year-over-year change of +10.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +5.3%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Biohaven Pharmaceutical Holding Company Ltd.